Tesofensine
Also known as: NS2330
Tesofensine is a small-molecule triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) — NOT a peptide. Originally developed by NeuroSearch for Parkinson's and Alzheimer's disease (which it failed to benefit) and repositioned for obesity by Saniona. Not FDA-approved in the US.
Pricing for Tesofensine
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Tesofensine
15 third-party tests across 8 vendors. Each card links to the full report.
For
Tesofensine
by Real Peptides
For
Tesofensine
by BioLongevity Labs· batch cmojb7n3x01d0kirxvvxt852q
For
Tesofensine
by BioLongevity Labs· batch TESO-0001
Purity not on file
For
Tesofensine
by Glacier Aminos· batch TES05002026-01
Purity not on file
For
Tesofensine
by Mile High Compounds· batch TSF-500-MH-02
Purity not on file
For
Tesofensine
by MedGe Peptides· batch 25F 019
Purity not on file
For
Tesofensine
by MedGe Peptides· batch 25E 019
Purity not on file
For
Tesofensine
by Profound Aminos· batch cmojb89ba01hxkirx3xc405y9
Purity not on file
For
Tesofensine
by Reta One Labs· batch TES500925
Purity not on file
For
Tesofensine
by Reta One Labs· batch TES5000925
Purity not on file
For
Tesofensine
by MedGe Peptides· batch 25E 019
Purity not on file
For
Tesofensine
by MedGe Peptides· batch 25E 019
Purity not on file
For
Tesofensine
by Peptide Supply Co.· batch TFE50004072026
Purity not on file
For
Tesofensine
by NG Peptide· batch TSC1
Purity not on file
For
Tesofensine
by Certified Peptides· batch 10082025
21 citations indexed for Tesofensine
rct · 2026
Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human
Rationale Monoamine triple reuptake inhibitors (TRIs) inhibit central dopamine, norepinephrine, and serotonin transporters, restoring functional monoamine neurotransmission.
Study · 2025
Structural basis for pharmacotherapeutic action of triple reuptake inhibitors
Most first-line pharmacotherapeutic strategies for depression aim to boost serotonin and norepinephrine levels. However, 35% of patients with depression do not respond adequately to these treatments or experience adverse side effects.
animal · 2025
Sex-specific effects of appetite suppressants on stereotypy in rats
This study investigated the sex-specific effects of commonly prescribed appetite suppressants on body weight and the manifestation of motor side effects, specifically stereotypy.
animal · 2025
Sex-specific effects of appetite suppressants and stereotypy in rats
This study investigated the sex-specific effects of commonly prescribed appetite suppressants on body weight and the manifestation of motor side effects, specifically stereotypy.
review · 2025
Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies
Obesity is a growing global health concern with widespread impacts on physical, psychological, and social well-being.
Study · 2025
Barriers, Limitations, and Experiences with Clinical Trials-Treatment in Rare Diseases with Prader-Willi Syndrome as an Example
Background/Objectives : Developing and implementing clinical trials for rare diseases is complicated by the incomplete understanding of the varied genotype and subsequent phenotypic differences of a condition, particularly when low numbers of subjects are enrolled in a study.